Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Apr 09, 2019
Study Says Canadian Cannabis Market Could Reach $5.2B By 2024: 4 Provinces To Watch - Benzinga

Study Says Canadian Cannabis Market Could Reach $5.2B By 2024: 4 Provinces To Watch - Benzinga

On Oct. 17, 2018, Canada made history by becoming the first G7 country and the second country overall to legalize adult-use cannabis.

Read More...

Related Ticker: ACB

ACB's RSI Indicator climbs out of oversold territory

The RSI Indicator for ACB moved out of oversold territory on July 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 38 similar instances when the indicator left oversold territory. In of the 38 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where ACB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on July 21, 2026. You may want to consider a long position or call options on ACB as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ACB just turned positive on July 10, 2026. Looking at past instances where ACB's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ACB entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.460) is normal, around the industry mean (46.654). P/E Ratio (19.440) is within average values for comparable stocks, (99.739). ACB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.668). ACB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.035). P/S Ratio (0.673) is also within normal values, averaging (114.968).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ACB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.1B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 13%. CPHI experienced the highest price growth at 1,218%, while SHPH experienced the biggest fall at -19%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 50%. For the same stocks of the Industry, the average monthly volume growth was -29% and the average quarterly volume growth was 52%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 65
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 14 (-100 ... +100)
View a ticker or compare two or three
ACB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a licensed producer of medical marijuana in Canada

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Other
Address
90B Street SW
Phone
+1 855 279-4652
Employees
1101
Web
https://www.auroramj.com
Interact to see
Advertisement
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.
Citigroup (C) is expected to report Q4 2025 EPS of $1.58, representing a 17.9% year-over-year increase, with revenue projected at $20.95 billion, up 7%. Bank of America (BAC) consensus estimates call for Q4 EPS of $0.96, up from $0.82, on revenue of $27.74 billion, reflecting 9.45% growth. JPMorgan Chase (JPM) is forecast to deliver Q4 EPS of $4.86, a modest 0.95% increase, with revenue expected to rise 8.13% to $46.25 billion.
Wall Street expects Infosys Q3 FY2026 EPS of $0.20, based on estimates from eight analysts, with revenue forecast at ₹452.37 billion (approximately $5.45 billion), compiled from 33 analysts.
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.
Bank of America (BAC) and Wells Fargo (WFC) will both report Q4 2025 earnings on January 14, 2026, creating a rare same-day, apples-to-apples comparison.
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
As 2026 gets underway, ether.fi’s governance token (ETHFI.X) is emerging as a focal point for traders seeking exposure to Ethereum’s rapidly expanding liquid restaking ecosystem. With total value locked climbing to $7.8 billion, ether.fi now ranks as the second-largest staking protocol after Lido, underscoring its growing influence in the Ethereum economy.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.
The Vanguard Russell 2000 ETF (VTWO) has entered 2026 with renewed technical strength, breaking through several key indicators that suggest a potential trend reversal. On January 2, 2026, VTWO’s Momentum Indicator moved decisively above zero, a signal often associated with the early stages of bullish cycles. This followed an earlier technical milestone in December 2025, when the 10-day moving average crossed above the 50-day, drawing attention from momentum and swing traders alike.
CAOS, the trading ticker for IRIS Energy Limited, is emerging as a standout performer in early 2026 as two powerful trends converge: Bitcoin’s renewed surge and explosive demand for AI-ready data infrastructure. As Bitcoin pushes higher and investors hunt for leveraged exposure to both crypto and artificial intelligence, CAOS has attracted increasing attention from retail and quantitative traders alike.
In a surprising development that has caught the attention of both retail traders and institutional quantitative desks, Rubicon Technology Inc. (NASDAQ: RBC) has surfaced as one of early 2026’s more compelling AI-driven momentum candidates. After a relatively quiet close to 2025, the Illinois-based materials company—long associated with synthetic sapphire technology—has begun to display unexpected price strength, triggering alerts across algorithmic trading platforms.
In January 2026, Dell Technologies (DELL) experienced a sharp pullback, sliding nearly 9% as investor concerns mounted over escalating memory costs. Shortages and price increases in DRAM and NAND have squeezed margins across Dell’s server and PC businesses. The pressure was amplified after management acknowledged at CES 2026 that AI-focused PC marketing underperformed expectations and that component constraints were “unprecedented.”
Prologis (PLD), the world’s largest logistics-focused REIT, reported fourth-quarter and full-year 2025 earnings on January 21, 2026, capping a standout year for the industrial real estate sector. Demand for modern logistics facilities remains elevated as e-commerce expansion and supply chain reconfiguration continue to reshape global distribution networks.
The Travelers Companies, Inc.(TRV), a major player in the property and casualty insurance market, reported fourth-quarter 2025 results on January 21, 2026, closing out a year marked by underwriting discipline despite volatile weather activity and pricing pressures. The results underscore Travelers’ ability to generate strong profitability while navigating challenges in personal insurance lines and heightened catastrophe risk.
FingerMotion, Inc. (NASDAQ: FNGR) reported fiscal third-quarter 2026 results on January 15, 2026, triggering a sharp selloff as investors reacted to a steep revenue decline and widening losses. Shares fell roughly 32% following the release after the mobile services provider disclosed a 32% year-over-year drop in revenue and a net loss of $1.67 million for the quarter ended November 30, 2025.
CSX Corporation, a major U.S. East Coast rail operator, reports fourth-quarter 2025 earnings after market close today, marking the end of a year characterized by uneven freight recovery. Comparing CSX with Canadian Pacific Kansas City (CP), now a transcontinental operator following its 2023 merger, highlights contrasting strategies within the North American rail sector.